<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CASPOFUNGIN <img border="0" src="../images/pr.gif"/></span><br/>(cas-po-fun'gin)<br/><span class="topboxtradename">Cancidas<br/></span><b>Classifications:</b> <span class="classification">anti-infective</span>; <span class="classification">antibiotic</span>; <span class="classification">echinocandin antifungal</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg and 70 mg powder for injection</p>
<h1><a name="action">Actions</a></h1>
<p>Caspofungin is an antifungal agent that inhibits the synthesis of an integral component of the fungal cell wall of susceptible
         <i>Aspergillus</i> species and <i>Candida</i> species.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Interferes with reproduction and growth of susceptible fungi.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of invasive aspergillosis in those refractory to or intolerant of other antifungal therapies; empirical therapy
         for presumed fungal infection with febrile neutropenia; treatment of candidemia and intra-abdominal abscesses, peritonitis,
         and pleural space infections due to <i>Candida</i>. Susceptible organisms include <i>Aspergillus</i> (<i>A. flavus</i>, <i>A. fumigatus</i>, <i>A. terreu</i>) and <i>Candida</i> (<i>C. albicans</i>, <i>C. glabrata</i>, <i>C. krusei</i>, <i>C. lusitaniae</i>, <i>C. parapsilosis</i>, <i>C. tropicalis</i>).
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Treatment of esophageal candidiasis with or without oropharyngeal candidiasis (thrush).</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to any component of this product; pregnancy (category C); not studied in patients with ESRF, or children.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Patients with moderate hepatic insufficiency; concomitant use of cyclosporine; lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Invasive <i>Aspergillosis</i>, Empirical Therapy, <i>Candida</i>
</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV Loading Dose:</span> 70 mg day 1 <span class="rdroute">IV Maintenance Dose:</span> 50 mg qd thereafter<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>Allow vial to come to room temperature.</li>
<li>A loading dose is usually administered on day 1 followed on subsequent days by a maintenance dose.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Reconstitute a 50 mg or 70 mg vial with 10.5 mL of NS, sterile water for injection, or bacteriostatic water for injection
                  to yield 5 mg/mL and 7 mg/mL, respectively. Mix gently until clear. Withdraw 10 mL of reconstituted solution and add to 250
                  mL of NS, ½NS, or 0.225% NS, or RL. <b>DO NOT</b> use diluents or IV solutions containing dextrose.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span>  Give slowly over at least 1 h. Do not coinfuse with any other medication.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> Any <b>dextrose</b>-containing solution. Do not mix or co-infuse with any other medications. 
               </p>
</td>
</tr>
</table>
<ul>
<li>Store IV solution for up to 24 h at 25° C (77° F) or below or 48 h at 2°8° C (36°46°
            F). Reconstituted solution should be stored at <img src="../images/special/lesserorequal.gif"/>25° C (<img src="../images/special/lesserorequal.gif"/>77°
            F) for 1 h prior to preparing the IV solution for infusion.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Anaphylaxis, chills, <span class="speceff-common">injection site reaction,</span> sensation of warmth. <span class="typehead">CNS:</span> Headache. <span class="typehead">CV:</span> Sinus tachycardia. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting,</span> diarrhea, abdominal pain. <span class="typehead">Hematologic/Lymphatic:</span>
<span class="speceff-common">Phlebitis, thrombophlebitis,</span> vasculitis, anemia. <span class="typehead">Hepatic:</span> Elevated liver enzymes. <span class="typehead">Metabolic:</span> Anorexia, <span class="speceff-common">hypokalemia</span>. <span class="typehead">Musculoskeletal:</span> Pain, myalgia. <span class="typehead">Respiratory:</span>
<span class="speceff-life">Acute respiratory distress syndrome</span>, dyspnea. <span class="typehead">Skin:</span> Rash, facial swelling, pruritus.  
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Cyclosporine</b> increases overall systematic exposure to caspofungin; inducers of drug clearance or mixed inducer/inhibitors (e.g., <b>carbamazepine,</b>
<b> dexamethasone,</b>
<b> efavirenz,</b>
<b> nelfinavir,</b>
<b> nevirapine,</b>
<b> phenytoin,</b>
<b> rifampin</b>) can decrease caspofungin levels; caspofungin decreases the overall systematic exposure to <b>tacrolimus</b>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Distribution:</span> 97% protein bound. <span class="typehead">Metabolism:</span> Liver and plasma to inactive metabolites. <span class="typehead">Elimination:</span> Equally excreted in urine and feces. <span class="typehead">Half-life:</span> 911 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for S&amp;S of hypersensitivity during IV infusion; frequently monitor IV site for thrombophlebitis.</li>
<li>Monitor for and report S&amp;S of fluid retention (e.g., weight gain, swelling, peripheral edema), especially with known cardiovascular
            disease. 
         </li>
<li>Lab tests: Baseline and periodic LFTs; periodic kidney function tests, serum electrolytes, and CBC with differential, platelet
            count.
         </li>
<li>Monitor blood levels of tacrolimus with concurrent therapy.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report immediately any of the following: facial swelling, wheezing, difficulty breathing or swallowing, tightness in chest,
            rash, hives, itching, or sensation of warmth.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>